Literature DB >> 29434983

Analysis of expression profile data identifies key genes and pathways in hepatocellular carcinoma.

Xuwei Jiang1, Yuqing Hao1.   

Abstract

The aims of the present study were to identify key genes and pathways associated with hepatocellular carcinoma (HCC) progression and predict compounds potentially associated with this type of carcinogenesis. The gene expression profile data of the GSE49515 dataset was obtained from the Gene Expression Omnibus database. The limma software package was used to identify the differentially expressed genes (DEGs). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed using the Biological Networks Gene Ontology tool and the Database for Annotation, Visualization and Integrated Discovery, respectively. The Michigan Molecular Interactions database plugin within the Cytoscape software platform was used to perform protein-protein interaction (PPI) network analysis. Chemical-gene interaction data for HCC were obtained from the Comparative Toxicogenomics Database to evaluate the associations between drugs and specific genes. A total of 302 DEGs, including 231 downregulated and 71 upregulated, were identified. Cytokine-cytokine receptor interaction and chemokine signaling were the significantly enriched pathways. Additionally, PPI network analysis indicated a total of 13 highest degree hub nodes, including FBJ murine osteosarcoma viral oncogene homolog (FOS) and DNA damage-inducible transcript 3 protein (DDIT3). Chemical-gene interaction analysis revealed that FUN and FOS were targeted by >500 compounds, while >200 genes were targeted by 2,3,7,8-tetrachlorodibenzodioxin and benzo(α)pyrene. In conclusion, the present study demonstrated that FOS, DDIT3, the cytokine-cytokine receptor interaction pathway and the chemokine signaling pathway may be key genes and pathways associated with the development of HCC. Furthermore, exposure to 2,3,7,8-tetrachlorodibenzodioxin or benzo(α)pyrene may lead to hepatocarcinogenesis.

Entities:  

Keywords:  differentially expressed genes; gene-drug interaction; hepatocellular carcinoma; kyoto encyclopedia of genes and genomes pathway analysis; protein-protein interaction network

Year:  2017        PMID: 29434983      PMCID: PMC5777365          DOI: 10.3892/ol.2017.7534

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  52 in total

1.  RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-kinase/myosin phosphatase target pathway.

Authors:  Wei Ma; Carmen Chak-Lui Wong; Edmund Kwok-Kwan Tung; Chun Ming Wong; Irene Oi-Lin Ng
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

2.  The HOX gene network in hepatocellular carcinoma.

Authors:  Clemente Cillo; Giulia Schiavo; Monica Cantile; Michel P Bihl; Paolo Sorrentino; Vincenza Carafa; Maria D' Armiento; Massimo Roncalli; Sebastiano Sansano; Raffaela Vecchione; Luigi Tornillo; Lucia Mori; Gennaro De Libero; Jessica Zucman-Rossi; Luigi Terracciano
Journal:  Int J Cancer       Date:  2011-05-30       Impact factor: 7.396

Review 3.  Targeting the HGF/c-MET pathway in hepatocellular carcinoma.

Authors:  Lipika Goyal; Mandar D Muzumdar; Andrew X Zhu
Journal:  Clin Cancer Res       Date:  2013-02-06       Impact factor: 12.531

4.  Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma.

Authors:  Eduard Ryschich; Paulius Lizdenis; Carina Ittrich; Axel Benner; Simone Stahl; Alf Hamann; Jan Schmidt; Percy Knolle; Bernd Arnold; Günter J Hämmerling; Ruth Ganss
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

5.  Insights into significant pathways and gene interaction networks in peripheral blood mononuclear cells for early diagnosis of hepatocellular carcinoma.

Authors:  Jian Xin Jiang; Chao Yu; Zhi Peng Li; Jie Xiao; Hao Zhang; Mei Yuan Chen; Cheng Yi Sun
Journal:  J Cancer Res Ther       Date:  2016 Apr-Jun       Impact factor: 1.805

6.  As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3β pathway.

Authors:  L Liu; Z Dong; J Liang; C Cao; J Sun; Y Ding; D Wu
Journal:  Oncogene       Date:  2013-07-01       Impact factor: 9.867

Review 7.  Hepatocellular carcinoma: clinical frontiers and perspectives.

Authors:  Jordi Bruix; Gregory J Gores; Vincenzo Mazzaferro
Journal:  Gut       Date:  2014-02-14       Impact factor: 23.059

8.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

9.  PathwayVoyager: pathway mapping using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database.

Authors:  Eric Altermann; Todd R Klaenhammer
Journal:  BMC Genomics       Date:  2005-05-03       Impact factor: 3.969

10.  Effects of benzo[a]pyrene exposure on human hepatocellular carcinoma cell angiogenesis, metastasis, and NF-κB signaling.

Authors:  Qian Ba; Junyang Li; Chao Huang; Hongling Qiu; Jingquan Li; Ruiai Chu; Wei Zhang; Dong Xie; Yongning Wu; Hui Wang
Journal:  Environ Health Perspect       Date:  2014-10-17       Impact factor: 9.031

View more
  3 in total

1.  An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma.

Authors:  Yifei Dai; Weijie Qiang; Kequan Lin; Yu Gui; Xun Lan; Dong Wang
Journal:  Cancer Immunol Immunother       Date:  2020-10-21       Impact factor: 6.968

2.  1,8 Cineole and Ellagic acid inhibit hepatocarcinogenesis via upregulation of MiR-122 and suppression of TGF-β1, FSCN1, Vimentin, VEGF, and MMP-9.

Authors:  Heba M I Abdallah; Sally A El Awdan; Rehab F Abdel-Rahman; Abdel Razik H Farrag; Rasha M Allam
Journal:  PLoS One       Date:  2022-01-26       Impact factor: 3.240

3.  Immune-related biomarkers shared by inflammatory bowel disease and liver cancer.

Authors:  Thong Ba Nguyen; Duy Ngoc Do; Thuy T P Nguyen; Truc Ly Nguyen; Tung Nguyen-Thanh; Ha Thi Nguyen
Journal:  PLoS One       Date:  2022-04-22       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.